Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel

Introduction: Conventional anti-androgen regimens were widely used as an initiation or combined androgen blockade (CAB) therapy in advanced prostate cancer patients. Currently, new androgen pathway inhibitors such as abiraterone acetate (AA) and enzalutamide had been proven effective in metastatic c...

Full description

Bibliographic Details
Main Authors:	Jian-Ri Li, Kun-Yuan Chiu, Shian-Shiang Wang, Cheng-Kuang Yang, Chuan-Shu Chen, Hao-Chung Ho, Chi-Feng Hung, Chen-Li Cheng, Chi-Rei Yang, Cheng-Che Chen, Shu-Chi Wang, Chia-Yen Lin, Chao-Hsiang Chang, Chiann-Yi Hsu, Yen-Chuan Ou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-11-01
Series:	Frontiers in Pharmacology
Subjects:	abiraterone acetate androgen deprivation therapy castration-resistant prostate cancer deferred combined androgen blockade docetaxel
Online Access:	http://journal.frontiersin.org/article/10.3389/fphar.2017.00836/full

Similar Items

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
by: Li-Wen Chang, et al.
Published: (2021-01-01)

The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy
by: Li-Hua Huang, et al.
Published: (2024-02-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Long-term outcome of robotic partial nephrectomy for renal angiomyolipoma
by: Chia-Yen Lin, et al.
Published: (2018-03-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.
by: Shian-Shiang Wang, et al.
Published: (2013-01-01)

Auto-recruit path for bone health screening of outpatient management system for patient with prostate cancer initiating androgen deprivation therapy
by: Chia-yen Lin, et al.
Published: (2023-12-01)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024-03-01)

Impact of H19 Polymorphisms on Prostate Cancer Clinicopathologic Characteristics
by: Ju-Chuan Hu, et al.
Published: (2020-08-01)

Intraoperative calculus or hemorrhage in transurethral seminal vesiculoscopy as a risk factor for recurrent hemospermia.
by: Cheng-En Mei, et al.
Published: (2022-01-01)

Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy
by: Li-Wen Chang, et al.
Published: (2023-03-01)

Associations between LncRNA <i>MALAT1</i> Polymorphisms and Lymph Node Metastasis in Prostate Cancer
by: Ju-Chuan Hu, et al.
Published: (2021-09-01)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
by: Karen A. Autio, et al.
Published: (2021-12-01)

Tumor Multifocality is a Significant Risk Factor of Urinary Bladder Recurrence after Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma: A Single-Institutional Study
by: Chuan-Shu Chen, et al.
Published: (2020-04-01)

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer
by: Takehiko Nakasato, et al.
Published: (2020-03-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

The prognostic impact of lymph node dissection for clinically node-negative upper urinary tract urothelial carcinoma in patients who are treated with radical nephroureterectomy.
by: Hsiang-Chen Hsieh, et al.
Published: (2022-01-01)

The prognostic impact of lymph node dissection for clinically node-negative upper urinary tract urothelial carcinoma in patients who are treated with radical nephroureterectomy
by: Hsiang-Chen Hsieh, et al.
Published: (2022-01-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

Renal volume matters: Assessing the association between excisional volume loss and renal function after partial nephrectomy
by: Gu-Shun Lai, et al.
Published: (2020-01-01)

Androgen-receptor positive lacrimal sac adenocarcinoma demonstrating long-lasting response to LHRH analogue plus abiraterone treatment
by: Elena eVagia, et al.
Published: (2015-02-01)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
by: Xin Hu, et al.
Published: (2019-12-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study.
by: Jian-Ri Li, et al.
Published: (2022-01-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?
by: Bertrand Tombal
Published: (2014-11-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
by: Michele Iuliani, et al.
Published: (2022-09-01)

Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study.
by: Wei-Cheng Chen, et al.
Published: (2023-01-01)

Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study
by: Wei-Cheng Chen, et al.
Published: (2023-01-01)

Choice of treatment options for metastatic hormone-sensitive prostate cancer
by: R. A. Gafanov, et al.
Published: (2020-12-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
by: Kouji Izumi, et al.
Published: (2022-07-01)

Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use
by: Cheng-Kuang Yang, et al.
Published: (2023-04-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients
by: Wu X, et al.
Published: (2020-06-01)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
by: Giorgia Gurioli, et al.
Published: (2020-09-01)

Ailanthone: a new potential drug for castration-resistant prostate cancer
by: Shihong Peng, et al.
Published: (2017-03-01)

Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
by: Leandro Blas, et al.
Published: (2022-01-01)

Unsuspected Prostate Cancer After Cystoprostatectomy: A Comparison Between Two Periods in Taiwan
by: Jian-Ri Li, et al.
Published: (2009-05-01)

Management of postoperative ileus after robot-assisted radical prostatectomy
by: Shu-Chi Wang, et al.
Published: (2019-01-01)